Yu et al. show that EGFR expression in EGFR‐mutant NSCLC patient‐derived exosomes is more than tenfold higher than that in healthy controls and exosomal EGFR levels may reflect the alteration of cancer EGFR after therapy.[207] Huang et al. have developed an efficient and sensitive quantitation method (HOLMES‐ExoPD‐L1) for exosomal PD‐L1 to predict cancer immunotherapy response. The gene discussed is EGFR; the disease is cancer.